{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:28:32Z","timestamp":1791300512980,"version":"4.1.0"},"reference-count":76,"publisher":"Elsevier BV","issue":"9","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.autrev.2013.03.003","type":"journal-article","created":{"date-parts":[[2013,3,26]],"date-time":"2013-03-26T13:30:24Z","timestamp":1364304624000},"page":"904-911","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":113,"title":["Complement associated pathogenic mechanisms in myasthenia gravis"],"prefix":"10.1016","volume":"12","author":[{"given":"Erdem","family":"T\u00fcz\u00fcn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Premkumar","family":"Christadoss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2013.03.003_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0404.2006.00605.x","article-title":"Immunology of disorders of neuromuscular transmission","volume":"183","author":"Vincent","year":"2006","journal-title":"Acta Neurol Scand Suppl"},{"key":"10.1016\/j.autrev.2013.03.003_bb0010","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1006\/clim.1999.4807","article-title":"Animal models of myasthenia gravis","volume":"94","author":"Christadoss","year":"2000","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2013.03.003_bb0015","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1172\/JCI29894","article-title":"Myasthenia gravis: past, present, and future","volume":"116","author":"Conti-Fine","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2013.03.003_bb0020","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S1568-9972(02)00146-5","article-title":"Autoantibodies to ion channels at the neuromuscular junction","volume":"2","author":"Lang","year":"2003","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2013.03.003_bb0025","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.autrev.2007.01.001","article-title":"Therapeutic options in autoimmune myasthenia gravis","volume":"6","author":"Garc\u00eda-Carrasco","year":"2007","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2013.03.003_bb0030","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.autrev.2013.03.011","article-title":"Ectopic germinal centers, BAFF and anti-B cell therapy in myasthenia gravis","volume":"12","author":"Berrih-Aknin","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2013.03.003_bb0035","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.autrev.2011.05.013","article-title":"Pathogenesis and therapies of immune-mediated myopathies","volume":"11","author":"Dalakas","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2013.03.003_bb0040","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1749-6632.1981.tb33730.x","article-title":"The immunopathology of acquired myasthenia gravis","volume":"377","author":"Engel","year":"1981","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.autrev.2013.03.003_bb0045","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/00005072-198003000-00005","article-title":"Ultrastructural localization of the terminal and lytic ninth complement component (C9) at the motor end-plate in myasthenia gravis","volume":"39","author":"Sahashi","year":"1980","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.autrev.2013.03.003_bb0050","first-page":"267","article-title":"Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations","volume":"52","author":"Engel","year":"1977","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.autrev.2013.03.003_bb0055","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/j.1749-6632.1987.tb51321.x","article-title":"Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis","volume":"505","author":"Howard","year":"1987","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.autrev.2013.03.003_bb0060","first-page":"197","article-title":"Mechanisms of acetylcholine receptor loss from the neuromuscular junction","volume":"90","author":"Engel","year":"1982","journal-title":"Ciba Found Symp"},{"key":"10.1016\/j.autrev.2013.03.003_bb0065","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.nmd.2005.11.005","article-title":"Predictive value of serum anti-C1q antibody levels in experimental autoimmune myasthenia gravis","volume":"16","author":"Tuzun","year":"2006","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.autrev.2013.03.003_bb0070","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.4049\/jimmunol.171.7.3847","article-title":"Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis","volume":"171","author":"Tuzun","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2013.03.003_bb0075","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3181\/00379727-105-26050","article-title":"Changes in serum complement activity in patients with myasthenia gravis","volume":"105","author":"Nastuk","year":"1960","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.autrev.2013.03.003_bb0080","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S0140-6736(76)92644-1","article-title":"Immune complexes in myasthenia gravis","volume":"2","author":"Casali","year":"1976","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2013.03.003_bb0085","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1212\/WNL.39.10.1359","article-title":"Diagnostic significance of IgG, C3, and C9 at the limb muscle motor end-plate in minimal myasthenia gravis","volume":"39","author":"Tsujihata","year":"1989","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2013.03.003_bb0090","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jneuroim.2004.08.002","article-title":"The role of complement in myasthenia gravis: serological evidence of complement consumption in vivo","volume":"158","author":"Romi","year":"2005","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2013.03.003_bb0095","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/mus.21398","article-title":"Correlation of C3 level with severity of generalized myasthenia gravis","volume":"40","author":"Liu","year":"2009","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2013.03.003_bb0100","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1001\/jama.291.19.2367","article-title":"Intravenous immunoglobulin in autoimmune neuromuscular diseases","volume":"291","author":"Dalakas","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.autrev.2013.03.003_bb0105","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1600-0404.1988.tb03650.x","article-title":"Plasma exchange in myasthenia gravis: changes in serum complement and immunoglobulins","volume":"78","author":"Thorlacius","year":"1988","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.autrev.2013.03.003_bb0110","doi-asserted-by":"crossref","first-page":"570","DOI":"10.3109\/00207454.2011.596293","article-title":"Evaluation of serum IgG subclass concentrations in myasthenia gravis patients","volume":"121","author":"Liu","year":"2011","journal-title":"Int J Neurosci"},{"key":"10.1016\/j.autrev.2013.03.003_bb0115","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1084\/jem.147.4.973","article-title":"Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis","volume":"147","author":"Lennon","year":"1978","journal-title":"J Exp Med"},{"key":"10.1016\/j.autrev.2013.03.003_bb0120","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00415-003-0956-9","article-title":"Effect of myasthenic immunoglobulin G on motor end-plate morphology","volume":"250","author":"Tsujihata","year":"2003","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2013.03.003_bb0125","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1212\/WNL.30.7.760","article-title":"Passive transfer of human myasthenia gravis to rats: 1. Electrophysiology of the developing neuromuscular block","volume":"30","author":"Howard","year":"1980","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2013.03.003_bb0130","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1212\/WNL.35.12.1748","article-title":"Complement-dependent lysis of cultured rat myotubes by myasthenic immunoglobulins","volume":"35","author":"Ashizawa","year":"1985","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2013.03.003_bb0135","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0165-5728(85)80007-2","article-title":"Complement-dependent toxicity of serum from myasthenic patients to muscle cells in culture","volume":"9","author":"Childs","year":"1985","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2013.03.003_bb0140","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/brain\/awn092","article-title":"IgG1 antibodies to acetylcholine receptors in \u2018seronegative\u2019 myasthenia gravis","volume":"131","author":"Leite","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.autrev.2013.03.003_bb0145","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1167\/iovs.07-0271","article-title":"A new mouse model of autoimmune ocular myasthenia gravis","volume":"48","author":"Yang","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.autrev.2013.03.003_bb0150","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/mus.22273","article-title":"Ocular and generalized myasthenia gravis induced by human acetylcholine receptor \u03b3 subunit immunization","volume":"45","author":"Wu","year":"2012","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2013.03.003_bb0155","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1196\/annals.1405.037","article-title":"Extraocular muscle susceptibility to myasthenia gravis: unique immunological environment?","volume":"1132","author":"Soltys","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.autrev.2013.03.003_bb0160","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.expneurol.2004.06.005","article-title":"Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis","volume":"189","author":"Kaminski","year":"2004","journal-title":"Exp Neurol"},{"key":"10.1016\/j.autrev.2013.03.003_bb0165","doi-asserted-by":"crossref","first-page":"8562","DOI":"10.4049\/jimmunol.179.12.8562","article-title":"Anti-C5 antibody treatment ameliorates weakness in experimentally acquired myasthenia gravis","volume":"179","author":"Zhou","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2013.03.003_bb0170","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/mus.1218","article-title":"The agrin\/muscle-specific kinase pathway: new targets for autoimmune and genetic disorders at the neuromuscular junction","volume":"25","author":"Liyanage","year":"2002","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2013.03.003_bb0175","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/01.wco.0000180660.57801.3f","article-title":"Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis","volume":"18","author":"Vincent","year":"2005","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.autrev.2013.03.003_bb0180","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.autrev.2013.03.004","article-title":"Diagnosis and therapy of myasthenia gravis with antibodies to muscle-specific kinase","volume":"12","author":"Evoli","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2013.03.003_bb0185","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/ana.20061","article-title":"Detection and characterization of MuSK antibodies in seronegative myasthenia gravis","volume":"55","author":"McConville","year":"2004","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2013.03.003_bb0190","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.autrev.2013.03.001","article-title":"Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4","volume":"12","author":"Verschuuren","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2013.03.003_bb0195","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1093\/brain\/aws025","article-title":"Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice","volume":"135","author":"Klooster","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.autrev.2013.03.003_bb0200","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.ajpath.2011.10.031","article-title":"Antibodies against muscle-specific kinase impair both presynaptic and postsynaptic functions in a murine model of myasthenia gravis","volume":"180","author":"Mori","year":"2012","journal-title":"Am J Pathol"},{"key":"10.1016\/j.autrev.2013.03.003_bb0205","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/ana.20341","article-title":"Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis","volume":"57","author":"Shiraishi","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2013.03.003_bb0210","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1159\/000330031","article-title":"Increased complement consumption in MuSK-antibody-positive myasthenia gravis patients","volume":"20","author":"T\u00fcz\u00fcn","year":"2011","journal-title":"Med Princ Pract"},{"key":"10.1016\/j.autrev.2013.03.003_bb0215","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.expneurol.2012.01.025","article-title":"Passive and active immunization models of MuSK-Ab positive myasthenia: electrophysiological evidence for pre and postsynaptic defects","volume":"234","author":"Viegas","year":"2012","journal-title":"Exp Neurol"},{"key":"10.1016\/j.autrev.2013.03.003_bb0220","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/ana.22312","article-title":"Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis","volume":"69","author":"Higuchi","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2013.03.003_bb0225","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/978-1-4615-1891-4_20","article-title":"Establishment of a mouse model of myasthenia gravis which mimics human myasthenia gravis pathogenesis for immune intervention","volume":"383","author":"Christadoss","year":"1995","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.autrev.2013.03.003_bb0230","doi-asserted-by":"crossref","first-page":"4093","DOI":"10.4049\/jimmunol.150.9.4093","article-title":"Age-related resistance to experimental autoimmune myasthenia gravis in rats","volume":"150","author":"Graus","year":"1993","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2013.03.003_bb0235","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1212\/WNL.29.2.179","article-title":"Passively transferred experimental autoimmune myasthenia gravis. Sequential and quantitative study of the motor end-plate fine structure and ultrastructural localization of immune complexes (IgG and C3), and of the acetylcholine receptor","volume":"29","author":"Engel","year":"1979","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2013.03.003_bb0240","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.4049\/jimmunol.140.8.2589","article-title":"C5 gene influences the development of murine myasthenia gravis","volume":"140","author":"Christadoss","year":"1988","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2013.03.003_bb0245","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1365-2249.2006.03198.x","article-title":"Complement membrane attack is required for endplate damage and clinical disease in passive experimental myasthenia gravis in Lewis rats","volume":"146","author":"Chamberlain-Banoub","year":"2006","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2013.03.003_bb0250","doi-asserted-by":"crossref","first-page":"11818","DOI":"10.1016\/S0021-9258(18)99030-7","article-title":"Structure of the murine fifth complement component (C5) gene. A large, highly interrupted gene with a variant donor splice site and organizational homology with the third and fourth complement component genes","volume":"266","author":"Haviland","year":"1991","journal-title":"J Biol Chem"},{"key":"10.1016\/j.autrev.2013.03.003_bb0255","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.4049\/jimmunol.148.12.3937","article-title":"Identification and characterization of the effector region within human C5a responsible for stimulation of IL-6 synthesis","volume":"148","author":"Morgan","year":"1992","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2013.03.003_bb0260","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0165-5728(00)00291-5","article-title":"The C5a complement activation peptide increases IL-1beta and IL-6 release from amyloid-beta primed human monocytes: implications for Alzheimer's disease","volume":"109","author":"O'Barr","year":"2000","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2013.03.003_bb0265","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jneuroim.2008.03.007","article-title":"C5a is not involved in experimental autoimmune myasthenia gravis pathogenesis","volume":"196","author":"Qi","year":"2008","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2013.03.003_bb0270","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.autrev.2005.02.004","article-title":"Mannose binding lectin: genetics and autoimmune disease","volume":"4","author":"Tsutsumi","year":"2005","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2013.03.003_bb0275","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jneuroim.2008.12.013","article-title":"Mannose-binding lectin pathway is not involved in myasthenia gravis pathogenesis","volume":"208","author":"Li","year":"2009","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2013.03.003_bb0280","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.autrev.2006.09.008","article-title":"The role of complement regulatory proteins (CD55 and CD59) in the pathogenesis of autoimmune hemocytopenias","volume":"6","author":"Ruiz-Arg\u00fcelles","year":"2007","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2013.03.003_bb0285","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1172\/JCI0216086","article-title":"Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection","volume":"110","author":"Lin","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2013.03.003_bb0290","doi-asserted-by":"crossref","first-page":"7098","DOI":"10.4049\/jimmunol.175.11.7098","article-title":"Cutting edge: murine CD59a modulates antiviral CD4+ T cell activity in a complement-independent manner","volume":"175","author":"Longhi","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2013.03.003_bb0295","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/sj.gene.6364296","article-title":"Analysis of the promoters and 5\u2032-UTR of mouse Cd59 genes, and of their functional activity in erythrocytes","volume":"7","author":"Qin","year":"2006","journal-title":"Genes Immun"},{"key":"10.1016\/j.autrev.2013.03.003_bb0300","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jneuroim.2006.07.016","article-title":"Complement regulator CD59 deficiency fails to augment susceptibility to actively induced experimental autoimmune myasthenia gravis","volume":"181","author":"T\u00fcz\u00fcn","year":"2006","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2013.03.003_bb0305","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.expneurol.2006.06.003","article-title":"Deficiency of decay accelerating factor and CD59 leads to crisis in experimental myasthenia","volume":"202","author":"Kaminski","year":"2006","journal-title":"Exp Neurol"},{"key":"10.1016\/j.autrev.2013.03.003_bb0310","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jneuroim.2012.01.003","article-title":"DAF\/CD55 and Protectin\/CD59 modulate adaptive immunity and disease outcome in experimental autoimmune myasthenia gravis","volume":"244","author":"Soltys","year":"2012","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2013.03.003_bb0315","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1476-9255-9-20","article-title":"Complement regulatory protein Crry deficiency contributes to the antigen specific recall response in experimental autoimmune myasthenia gravis","volume":"9","author":"Soltys","year":"2012","journal-title":"J Inflamm (Lond)"},{"key":"10.1016\/j.autrev.2013.03.003_bb0320","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.4049\/jimmunol.142.8.2654","article-title":"Inhibition of acute passive transfer experimental autoimmune myasthenia gravis with Fab antibody to complement C6","volume":"142","author":"Biesecker","year":"1989","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2013.03.003_bb0325","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0165-5728(96)00144-0","article-title":"Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis","volume":"71","author":"Piddlesden","year":"1996","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2013.03.003_bb0330","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.4049\/jimmunol.152.11.5477","article-title":"Soluble recombinant complement receptor 1 inhibits inflammation and demyelination in antibody-mediated demyelinating experimental allergic encephalomyelitis","volume":"152","author":"Piddlesden","year":"1994","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2013.03.003_bb0335","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0304-3940(95)12115-K","article-title":"Soluble complement receptor type 1 inhibits experimental autoimmune neuritis in Lewis rats","volume":"200","author":"Jung","year":"1995","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.autrev.2013.03.003_bb0340","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1046\/j.1365-2249.2000.01129.x","article-title":"Soluble complement receptor one (sCR1) inhibits the development and progression of rat collagen-induced arthritis","volume":"119","author":"Goodfellow","year":"2000","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2013.03.003_bb0345","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/ana.21536","article-title":"Novel complement inhibitor limits severity of experimentally myasthenia gravis","volume":"65","author":"Soltys","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2013.03.003_bb0350","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.autrev.2008.07.019","article-title":"Infections as triggers and complications of systemic lupus erythematosus","volume":"8","author":"Doria","year":"2008","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2013.03.003_bb0355","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.4049\/jimmunol.1101749","article-title":"Functional complement C1q abnormality leads to impaired immune complexes and apoptotic cell clearance","volume":"187","author":"Roumenina","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2013.03.003_bb0360","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jneuroim.2006.10.014","article-title":"Pros and cons of treating murine myasthenia gravis with anti-C1q antibody","volume":"182","author":"T\u00fcz\u00fcn","year":"2007","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2013.03.003_bb0365","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.autrev.2008.06.006","article-title":"Anti-C1q autoantibodies","volume":"7","author":"Kallenberg","year":"2008","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2013.03.003_bb0370","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.autrev.2011.04.031","article-title":"Management of refractory cases of catastrophic antiphospholipid syndrome","volume":"10","author":"Espinosa","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2013.03.003_bb0375","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1358\/dot.2007.43.8.1130446","article-title":"Eculizumab: a novel therapy for paroxysmal nocturnal hemoglobinuria","volume":"43","author":"Zareba","year":"2007","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.autrev.2013.03.003_bb0380","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1517\/14656566.2012.705831","article-title":"Treatment strategies for myasthenia gravis: an update","volume":"13","author":"D\u00edaz-Manera","year":"2012","journal-title":"Expert Opin Pharmacother"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997213000293?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997213000293?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T14:49:06Z","timestamp":1688136546000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997213000293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":76,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S1568997213000293"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2013.03.003","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complement associated pathogenic mechanisms in myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2013.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}